Skip to main content

Advertisement

Table 3 Prevalence of molecular markers associated with P. falciparum resistance to CQ and SP in symptomatic and asymptomatic children

From: Prevalence of the molecular marker of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in Benin seven years after the change of malaria treatment policy

Molecular marker Population n (%) Symptomatic n (%) Asymptomatic n (%) p-value
T76 (n = 213) 200 (93.9%)* 68/72 94.4%) 132/141 (93.6%) 1a
Y86 (n = 212) 121 (57.1%) 29/71 (40.8%) 92/141 (65.2%) 0.03b
T76Y86 (n = 212) 117 (55.2%) 28/71 (39.4%) 89/140 (63.6%) 0.03b
G437 (n = 210) 150 (71.4%) 48/73 (65.8%) 102/137 (74.5%) 0.42b
E540 (n = 210) 0% 0% 0%  
I51 (n = 212) 204 (96.2%) 69/73 (94.5%) 135/139 (97.1%) 0.45a
R59 (n = 212) 199 (93.9%) 69/73 (94.5%) 130/139 (93.5%) 1a
N108 (n = 212) 207 (97.6%) 71/73 (97.3%) 136/139 (97.8%) 0.72a
IRN1 (n = 212) 194 (91.5%) 67/73 (91.8%) 127/139 (91.4%) 0.61b
IRNG2 (n = 210) 138 (65.7%) 44/73 (60.3%) 94/137 (68.6%) 0.15b
  1. 1pfdhfr triple mutants (I51, R59, and N108).
  2. 2pfdhfr/pfdhps quadruple mutants (pfdhfr I51, R59, N108 and pfdhps G437).
  3. *p < 0.001 of Chi 2 test (comparison between T76 and Y86, T76 and T76Y86).
  4. a p-value of fisher test.
  5. b p-value of Chi 2 test.